Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Veschi, Veronica ^a   Petroni, Marialaura ^b   Cardinali, Beatrice ^c   Dominici, Carlo ^d,e   Screpanti, Isabella ^b   Frati, Luigi ^a   Bartolazzi, Armando ^f,g   Gulino, Alberto ^b   Giannini, Giuseppe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; MYC PROTEIN; NUTLIN 3; PROTEIN P53; TUMOR MARKER;

APOPTOSIS; ARTICLE; CELL KILLING; CELL PROTECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOPROTECTION; DNA DAMAGE; GALECTIN 3; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMIDAZOLES; MODELS, BIOLOGICAL; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHENOTYPE; PIPERAZINES; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869077063     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049139     Document Type: Article

References (67)

1. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, et al. (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289-297.
2. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, et al. (2009) Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol 27: 365-370.
3. Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, et al. (2009) Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 27: 1014-1019.
4. Meyer N, Penn LZ, (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
5. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM, (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. Embo J 16: 2985-2995.
6. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, et al. (2007) Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 30: 1189-1196.
7. Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, et al. (2003) Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95: 1394-1403.
8. Zornig M, Busch G, Beneke R, Gulbins E, Lang F, et al. (1995) Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes. Oncogene 11: 2165-2174.
9. Kobayashi M, Hjerling-Leffler J, Ernfors P, (2006) Increased progenitor proliferation and apoptotic cell death in the sensory lineage of mice overexpressing N-myc. Cell Tissue Res 323: 81-90.
10. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, et al. (2006) The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 66: 2826-2833.
11. Keshelava N, Seeger RC, Groshen S, Reynolds CP, (1998) Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405.
12. Bell E, Premkumar R, Carr J, Lu X, Lovat PE, et al. (2006) The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 5: 2639-2647.
13. Petroni M, Veschi V, Prodosmo A, Rinaldo C, Massimi I, et al. (2011) MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. Mol Cancer Res 9: 67-77.
14. Gamble LD, Kees UR, Tweddle DA, Lunec J, (2011) MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 31: 752-763.
15. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, et al. (2009) Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 101: 1562-1574.
16. Meek DW, (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.
17. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, et al. (2003) The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197: 93-98.
18. Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, et al. (2007) p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 6: 2685-2696.
19. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, et al. (2008) Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10: 1268-1274.
20. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, et al. (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 70: 1377-1388.
21. Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F, (2009) Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ 16: 1563-1572.
22. Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, et al. (2010) High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res 16: 1108-1118.
23. Dumic J, Dabelic S, Flogel M, (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760: 616-635.
24. Califice S, Castronovo V, Bracke M, van den Brule F, (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23: 7527-7536.
25. Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JL, et al. (2010) Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 1800: 181-189.
26. Fukumori T, Kanayama HO, Raz A, (2007) The role of galectin-3 in cancer drug resistance. Drug Resist Updat 10: 101-108.
27. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, et al. (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Molecular and cellular biology 24: 4395-4406.
28. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A, (1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57: 5272-5276.
29. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, et al. (2006) Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66: 3114-3119.
30. Cecchinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, et al. (2006) Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 26: 4746-4757.
31. Lavra L, Rinaldo C, Ulivieri A, Luciani E, Fidanza P, et al. (2011) The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One 6: e20665.
32. Lavra L, Ulivieri A, Rinaldo C, Dominici R, Volante M, et al. (2008) Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol.
33. Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL, et al. (2002) Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells. Oncogene 21: 6132-6137.
34. Thiele CJ (1998) Neuroblastoma Cell Lines. In: Master J editor. Human Cell Culture. Lancaster, UK: Kluwer Academic Publishers. 21-53.
35. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, et al. (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13: 803-812.
36. Giammarioli AM, Gambardella L, Barbati C, Pietraforte D, Tinari A, et al. (2012) Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. International journal of cancer Journal international du cancer 131: E337-347.
37. Mellone M, Rinaldi C, Massimi I, Petroni M, Veschi V, et al. (2008) Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis. Neoplasia 10: 773-781.
38. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, et al. (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132.
39. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, et al. (2009) HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 69: 6241-6248.
40. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, et al. (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
41. Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, et al. (2001) Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18: 787-792.
42. Dominici C, Negroni A, Romeo A, Castello MA, Clerico A, et al. (1989) Association of near-diploid DNA content and N-myc amplification in neuroblastomas. Clin Exp Metastasis 7: 201-211.
43. Giannini G, Kim CJ, Marcotullio LD, Manfioletti G, Cardinali B, et al. (2000) Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br J Cancer 83: 1503-1509.
44. Fulda S, Lutz W, Schwab M, Debatin KM, (1999) MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18: 1479-1486.
45. Giannini G, Di Marcotullio L, Ristori E, Zani M, Crescenzi M, et al. (1999) HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. Cancer Res 59: 2484-2492.
46. Judware R, Culp LA, (1995) Over-expression of transfected N-myc oncogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit. Oncogene 11: 2599-2607.
47. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, et al. (2003) Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 195: 111-119.
48. Yu F, Finley RL Jr, Raz A, Kim HR, (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277: 15819-15827.
49. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
50. Martins CP, Brown-Swigart L, Evan GI, (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334.
51. Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
52. Cheok CF, Verma CS, Baselga J, Lane DP, (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
53. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, et al. (2005) The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 102: 731-736.
54. Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, et al. (2005) High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res 65: 8308-8316.
55. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, et al. (2004) Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6: 625-630.
56. Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, et al. (2005) Molecular mechanism of HMGA1 deregulation in human neuroblastoma. Cancer Lett 228: 97-104.
57. Cerignoli F, Ambrosi C, Mellone M, Assimi I, di Marcotullio L, et al. (2004) HMGA molecules in neuroblastic tumors. Ann N Y Acad Sci 1028: 122-132.
58. Kim MK, Sung CO, Do IG, Jeon HK, Song TJ, et al. (2011) Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 16: 352-358.
59. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H, et al. (2005) Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 25: 3117-3121.
60. Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, et al. (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31: 277-285.
61. Idikio H, (1998) Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12: 1287-1290.
62. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, et al. (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8: 2570-2575.
63. Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, et al. (2000) Decreased galectin-3 expression in prostate cancer. Prostate 44: 118-123.
64. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, et al. (2008) Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 9: 543-549.
65. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, et al. (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357: 1644-1650.
66. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214.
67. Reynolds CP, Tomayko MM, Donner L, Helson L, Seeger RC, et al. (1988) Biological classification of cell lines derived from human extra-cranial neural tumors. Progress in clinical and biological research 271: 291-306.